Pharma Foods International Co Ltd

Pharma Foods International maintains a debt-to-equity ratio of 1.1 and a current ratio of 1.19, indicating moderate leverage and liquidity coverage. The company holds 9.16 billion JPY in cash and equivalents but reports negative net cash after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity of 3.19% and return on assets of 1.13%, both below the industry median for biotechnology firms. Operating income of 2.25 billion JPY reflects a narrow margin, with net income of 368 million JPY, suggesting pressure from cost structures or competitive pricing. Revenue is distributed across three segments: B2C, B2B, and Biomedical. The B2C segment sells directly to consumers, while the B2B segment focuses on manufacturing and supplying functional ingredients. The Biomedical segment is dedicated to research on intractable diseases. No geographic concentration is disclosed, but the company operates primarily in Japan. Outlook for FY2024 shows a 5.2% revenue increase to 68.5 billion JPY, driven by B2B expansion and Biomedical R&D. However, operating cash flow remains negative at -1.09 billion JPY, and free cash flow is -537 million JPY, indicating ongoing reinvestment needs. Risk assessment highlights medium liquidity risk due to negative net cash and a debt load of 12.66 billion JPY. Dilution risk is low, with no near-term equity issuance plans. Adjustments in custom valuations reflect conservative capital structure assumptions. Recent filings include a 2023 annual report disclosing R&D progress in autoimmune disease therapies and a 2024 Q1 earnings call noting supply chain cost pressures. No material regulatory or litigation events were reported.